538 related articles for article (PubMed ID: 12101426)
1. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
2. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
Ishizaki Y; Ikeda S; Fujimori M; Shimizu Y; Kurihara T; Itamoto T; Kikuchi A; Okajima M; Asahara T
Int J Oncol; 2004 May; 24(5):1077-83. PubMed ID: 15067328
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
[TBL] [Abstract][Full Text] [Related]
6. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
7. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
8. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
9. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
Prange W; Breuhahn K; Fischer F; Zilkens C; Pietsch T; Petmecky K; Eilers R; Dienes HP; Schirmacher P
J Pathol; 2003 Oct; 201(2):250-9. PubMed ID: 14517842
[TBL] [Abstract][Full Text] [Related]
10. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma.
Ueta T; Ikeguchi M; Hirooka Y; Kaibara N; Terada T
Oncol Rep; 2002; 9(6):1197-203. PubMed ID: 12375019
[TBL] [Abstract][Full Text] [Related]
11. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.
Park JY; Park WS; Nam SW; Kim SY; Lee SH; Yoo NJ; Lee JY; Park CK
Liver Int; 2005 Feb; 25(1):70-6. PubMed ID: 15698401
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
Moreno-Bueno G; Hardisson D; Sánchez C; Sarrió D; Cassia R; García-Rostán G; Prat J; Guo M; Herman JG; Matías-Guiu X; Esteller M; Palacios J
Oncogene; 2002 Nov; 21(52):7981-90. PubMed ID: 12439748
[TBL] [Abstract][Full Text] [Related]
13. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
Anna CH; Sills RC; Foley JF; Stockton PS; Ton TV; Devereux TR
Cancer Res; 2000 Jun; 60(11):2864-8. PubMed ID: 10850429
[TBL] [Abstract][Full Text] [Related]
14. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway.
Torbenson M; Lee JH; Choti M; Gage W; Abraham SC; Montgomery E; Boitnott J; Wu TT
Mod Pathol; 2002 Mar; 15(3):189-96. PubMed ID: 11904335
[TBL] [Abstract][Full Text] [Related]
15. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
Chen YW; Jeng YM; Yeh SH; Chen PJ
Hepatology; 2002 Oct; 36(4 Pt 1):927-35. PubMed ID: 12297840
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
Buendia MA
Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.
Yan D; Wiesmann M; Rohan M; Chan V; Jefferson AB; Guo L; Sakamoto D; Caothien RH; Fuller JH; Reinhard C; Garcia PD; Randazzo FM; Escobedo J; Fantl WJ; Williams LT
Proc Natl Acad Sci U S A; 2001 Dec; 98(26):14973-8. PubMed ID: 11752446
[TBL] [Abstract][Full Text] [Related]
19. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.
Legoix P; Bluteau O; Bayer J; Perret C; Balabaud C; Belghiti J; Franco D; Thomas G; Laurent-Puig P; Zucman-Rossi J
Oncogene; 1999 Jul; 18(27):4044-6. PubMed ID: 10435629
[TBL] [Abstract][Full Text] [Related]
20. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
Koch A; Denkhaus D; Albrecht S; Leuschner I; von Schweinitz D; Pietsch T
Cancer Res; 1999 Jan; 59(2):269-73. PubMed ID: 9927029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
